Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

被引：0
|
作者：
Ralf Gold
Ernst-Wilhelm Radue
Gavin Giovannoni
Krzysztof Selmaj
Eva Kubala Havrdova
Xavier Montalban
Dusan Stefoski
Till Sprenger
Randy R. Robinson
Sami Fam
Jonathan Smith
Spyros Chalkias
Giorgio Giannattasio
Gabriel Lima
Wanda Castro-Borrero
机构：
[1] St. Josef-Hospital/Ruhr-University Bochum,Medical Image Analysis Center
[2] University Hospital Basel,Barts and The London School of Medicine and Dentistry
[3] Queen Mary University of London,Department of Neurology
[4] University of Warmia and Mazury,Department of Neurology, First Faculty of Medicine
[5] Charles University,undefined
[6] Hospital Vall d’Hebron University,undefined
[7] Rush University Medical Center,undefined
[8] DKD Helios Klinik Wiesbaden,undefined
[9] AbbVie Inc.,undefined
[10] Biogen,undefined
[11] Biogen,undefined
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
Daclizumab beta; Relapsing–remitting multiple sclerosis; SELECTED; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2851 / 2864
页数：13
相关论文
共 50 条
  • [41] Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
    Goemans, Nathalie M.
    Tulinius, Mar
    van den Hauwe, Marleen
    Kroksmark, Anna-Karin
    Buyse, Gunnar
    Wilson, Rosamund J.
    van Deutekom, Judith C.
    de Kimpe, Sjef J.
    Lourbakos, Afrodite
    Campion, Giles
    PLOS ONE, 2016, 11 (09):
  • [42] Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
    Gevaert, Philippe
    Saenz, Rebecca
    Corren, Jonathan
    Han, Joseph K.
    Mullol, Joaquim
    Lee, Stella E.
    Ow, Randall A.
    Zhao, Rui
    Howard, Monet
    Wong, Kit
    Islam, Lutaf
    Ligueros-Saylan, Monica
    Omachi, Theodore A.
    Bachert, Claus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (03) : 957 - +
  • [43] Safety and tolerability of fingolimod in relapsing-remitting multiple sclerosis: results from a large open-label clinical trial
    Laroni, A.
    Brogi, D.
    Morra, V. Brescia
    Guidi, L.
    Pozzilli, C.
    Comi, G.
    Lugaresi, A.
    Turrini, R.
    Raimondi, D.
    Uccelli, A.
    Mancardi, G. L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 104 - 105
  • [44] Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis
    Boster, Aaron L.
    Ford, Corey C.
    Neudorfer, Orit
    Gilgun-Sherki, Yossi
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (06) : 575 - 586
  • [45] Long-term treatment with zonisamide: Results of a 2 year open-label extension study
    Wroe, S.
    Duncan, R.
    EPILEPSIA, 2006, 47 : 138 - 138
  • [46] Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis From Two Phase 3 Trials and an Open-Label Extension Study
    Selmaj, K. W.
    Cohen, J. A.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H.
    Montalban, X.
    Kappos, L.
    Sheffield, J. K.
    Krakovich, A.
    Cheng, C.
    Riolo, J.
    Silva, D.
    Cree, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 56 - 57
  • [47] Design of a multicentre, open-label extension study to evaluate the long-term safety, immunogenicity, anti efficacy of natalizumab in patients with multiple sclerosis
    O'Connor, P
    Toal, M
    Wilmer-Hulme, A
    Yang, M
    Panzara, M
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S261 - S261
  • [48] Correlations Between Early MRI Parameters and Long-Term Clinical Outcomes in Phase 3 and Open-Label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
    Arnold, Douglas
    Freeman, Leorah
    Hartung, Hans-Peter
    Montalban, Xavier
    Cohen, Jeffrey
    Bar-Or, Amit
    Steinman, Lawrence
    DeLuca, John
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Pachai, Chahin
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1050 - 1051
  • [49] Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension
    Giovannoni, Gavin
    Granziera, Cristina
    Mao-Draayer, Yang
    Cutter, Gary
    Kalbus, Oleksandr
    Staikov, Ivan
    Dufek, Michal
    Saubadu, Stephane
    Bejuit, Raphael
    Smyth, Brendan
    Djukic, Biljana
    Truffinet, Philippe
    Wallstroem, Erik
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 64 - 65
  • [50] Long-term (up to 26 years), open-label, compassionate use study of glatiramer acetate in relapsing-remitting multiple sclerosis
    Miller, A
    Spada, V
    Beerkircher, D
    Kreitman, RR
    Kadosh, S
    MULTIPLE SCLEROSIS JOURNAL, 2005, 11 : S84 - S84
12345